SIU 2017: Novel Classification of Gleason 7 Prostate Cancer According to the Discrepancy between Biopsy and Final Gleason Score after Radical Prostatectomy

Lisbon, Portugal (UroToday.com) This study, presented by Dr. Cho, evaluated the impact of pathological upgrading of Gleason score 7 prostate cancer on the risk of biochemical recurrence after radical prostatectomy (RP).

A total of 1678 consecutive patients who had biopsy proven prostate cancer and underwent RP with postoperative Gleason score (GS) of 7 were retrospectively reviewed. The patients were then divided into 4 groups: 

1. upgraded GS 3+4
2. non-upgraded GS 3+4
3. upgraded GS 4+3
4. non-upgraded GS 4+3

Kaplan-Meier survival curve and multivariable models were developed to examine the influence of pathological upgrading of GS 7 on the risk of biochemical recurrence.

Mean age of the non-upgraded GS 4+3 was significantly higher than other groups. Five year biochemical recurrence free survival rate was 85%, 73%, 69% and 60% in the 4 groups, respectively. No significant difference was found between group 2 and group 3.

The authors concluded that that the information on pathologic upgrading could help provide more detailed information on the risk of biochemical recurrence in GS 7 disease.


Presented by: Cho MH
Affiliation: Medical Center, Seoul, South Korea

Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre.Twitter: @GoldbergHanan at the 37th Congress of Société Internationale d’Urologie - October 19-22, 2017- Lisbon, Portugal





E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe